Precision Biosciences (DTIL) Cash & Current Investments (2018 - 2026)

Precision Biosciences (DTIL) has reported Cash & Current Investments for 9 consecutive years, with $28.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Current Investments fell 63.36% year-over-year to $28.3 million; the TTM figure through Mar 2026 stood at $28.3 million (down 63.36% YoY), while the FY2025 annual figure was $115.6 million, up 402.94% from the prior year.
• Cash & Current Investments declined to $28.3 million in Q1 2026 per DTIL's latest filing, from $115.6 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $212.1 million in Q3 2022 and bottomed at $22.6 million in Q2 2025.
• Historically, Cash & Current Investments has averaged $112.4 million across 5 years, with a median of $116.7 million in 2023.
• On a YoY basis, Cash & Current Investments climbed as much as 402.94% in 2025 and fell as far as 81.74% in 2025.
• Precision Biosciences' Cash & Current Investments stood at $189.6 million in 2022, then plunged by 38.45% to $116.7 million in 2023, then sank by 80.3% to $23.0 million in 2024, then soared by 402.94% to $115.6 million in 2025, then sank by 75.52% to $28.3 million in 2026.
• Business Quant data shows DTIL's Cash & Current Investments at $28.3 million in Q1 2026, $115.6 million in Q4 2025, and $44.9 million in Q3 2025.